Free UK Delivery on orders over £49

Vanguard 7 (25 doses)

Item Number: VANGUARD7

Sale Vanguard 7 (25 doses)
  • 25 doses

    Usually dispatched on Friday if ordered within 13 hours and 4 minutes

    Was £186.00 Now £185.19

    Web code: Q10561

Total: £0.00

Choose quantity to add to basket

 

 


Browse other products from the Vanguard product range

Description

Presentation
An injection in two fractions:
Vanguard DA2Pi: freeze-dried fraction containing live attenuated canine distemper virus, Snyder Hill strain = 103.0 CCID50, live attenuated canine adenovirus Type 2, Manhattan strain = 103.2 CCID50 and live attenuated parainfluenzavirus, NL-CPI-5 strain = 106.0 CCID­50.
Vanguard CPV-L: liquid fraction containing live attenuated canine parvovirus, NL-35-D strain, low passage = 107.0 CCID50, inactivated Leptospira canicola = PD40 and inactivated Leptospira icterohaemorrhagiae = PD40.

Uses
For the active immunisation of healthy puppies and dogs to prevent mortality and clinical signs due to canine distemper virus infections, to prevent clinical signs and reduce infection or excretion due to canine parvovirus infections, to reduce mortality and clinical signs due to canine adenovirus type 1 infections, to reduce clinical signs and infection or excretion due to canine adenovirus type 2 infections, to reduce clinical signs and infection due to Leptospira canicola and icterohaemorrhagiae, and to reduce pathological signs of disease caused by canine parainfluenzavirus infections.
Onset of immunity occurs by approximately two weeks after the last dose of the Basic Vaccination Scheme.
The duration of immunity for canine distemper virus, canine parvovirus, canine adenovirus type 1 and 2 and the leptospiral components is at least 12 months. However, the duration of immunity for canine parainfluenzavirus has not been determined.

Dosage and administration
Reconstitute one vial of the freeze-dried fraction (Vanguard DA2Pi) aseptically using the contents of one vial of the liquid fraction (Vanguard CPV-L) as diluent. Shake well and immediately inject the entire contents of the reconstituted vial (1 ml) subcutaneously. Do not use chemically sterilized syringes or needles, as these will interfere with the effectiveness of the vaccine.
Basic Vaccination Scheme:
Puppies younger than 10 weeks of age: Two doses of Vanguard 7 at least 14 days apart. The first dose can be given as young as 7 weeks of age. The second dose should not be given until at least 10 weeks of age.
Puppies 10 weeks of age and older: A single dose of Vanguard 7, followed by a single dose of Vanguard Lepto ci at least 14 days later.
Booster Vaccination:
Leptospiral components – annual booster vaccination is recommended.
Viral components – annual booster vaccination is recommended. However, should Veterinary Surgeons conduct a risk-benefit analysis for individual animals to determine the frequency of revaccination with Vanguard 7, they should be aware of the following information. Serological data has indicated that most dogs, when given at least the first annual booster, can maintain protective levels of immunity to the viral components of Vanguard 7 for up to 4 years. For further information please contact the company.

Contra-indications, warnings, etc
Do not vaccinate unhealthy or pregnant animals.
Vaccinated dogs may have a transient swelling 4-6 hours after vaccination which resolves after approximately 7 days. If a systemic anaphylactic reaction occurs (e.g. vomiting) administer adrenaline or an equivalent.
Occasional, transient swellings may occur at the injection site after vaccination with an overdose. No treatment is necessary in most cases of overdose. However, if a systemic anaphylactic reaction occurs (e.g. vomiting) administer adrenaline or an equivalent.
The canine adenovirus Type 2 and canine parvovirus vaccinal strains may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated animals separated from non-vaccinated animals.
High levels of maternally derived antibodies (MDA) may interfere with the response to vaccination. Although the vaccine has been shown to be efficacious in the presence of levels of MDA that are likely to be encountered under field conditions, where for any reason it is likely that particularly high levels of MDA are present (for example against the CPV component), this should be taken into account when planning the timing of vaccinations.
Operator warning:
In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.

Pharmaceutical precautions
Store and transport at 2°C - 8°C. Do not freeze.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with this product.
Do not mix with any other vaccine or immunological product.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
For animal treatment only.
Keep out of reach of children.

Legal category
POM-V (previously POM).

Packaging Quantities
Packs contain 25 vials of the Vanguard DA2Pi freeze-dried fraction and 25 vials of Vanguard CPV-L liquid fraction. Packs of disposable syringes with needles are also available.

Further information
The CAV-2 strain used in Vanguard 7 has not been associated in either laboratory or field studies with corneal opacity (”blue eye”) or uveitis associated with adenovirus type 1 (CAV-1).
Canine parvovirus disease in kennels and pet shops is a problem of intensive husbandry and must be treated as such. Without careful professional attention to management practices in such places, successful disease control may be difficult to achieve.
When used in accordance with the recommended vaccination regime, Vanguard 7 can aid in the reduction of environmental contamination with canine parvovirus.

Marketing authorisation number
Vm 00057/4167.

Data Sheets

VANGUARD7: Data Sheet

Reviews